- About WXPress
- WXPress is your window into the world of WuXi AppTec and our global partners.
- Sitemap
- Events
- Contact
- Please reach out with any business inquires.
- communications@wuxiapptec.com
© 2026 WuXi AppTec. All Rights Reserved.Privacy Policy
October 26, 2023 ~ October 26, 2023
8AM – 10:15 AM PDT and 8PM – 10:15 PM PDT
Dear colleagues and friends,
We recognize the pivotal roles breakthrough science plays in transforming patients' lives, and the challenges in bridging the gap between science and development. It is our pleasure to invite you to an exclusive global online event dedicated to unraveling this very conundrum: Translating Science into Meaningful Therapies.
For the convenience of all time zones, we will air twice on October 26 at 8AM – 10:00 AM PDT and 8PM – 10:00 PM PDT. Please register now for a complimentary ticket, and updates on the entire series.
Can’t make it to either live session? Don’t worry, we will send you an on-demand link after the event so you don’t miss out on any valuable insights.
WuXi AppTec is committed to fostering innovation as a dedicated enabler, a trusted partner, and an active contributor to advancing breakthroughs for patients. By working together, we can think boldly and act boldly in addressing global health challenges!
Hui Cai, Program Chair and Vice President, WuXi AppTec
Paulo Fontoura, Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases Clinical Development, Roche
Edward Hu, Vice Chairman, WuXi AppTec
Jim Broderick, CEO & Founder, Palleon Pharmaceuticals
Dina Burkitbayeva, CEO & Co-Founder, Freedom Biosciences
Tianjing (TJ) Deng, CEO & Co-Founder, Pyrotech Therapeutics
Vishal Doshi, Chairman & CEO, AUM Biosciences
Zachary Hornby, CEO, President & Director, Boundless Bio
Danuta Jeziorska, CEO & Co-Founder, Nucleome Therapeutics
Philip Kantoff, Co-Founder & CEO, Convergent Therapeutics
Michelle Arkin, Professor & Chair, Pharmaceutical Chemistry, UCSF
Eric Fischer, Director, Chemical Biology Program, Dana-Farber Cancer Institute; Professor, Harvard Medical School
Kevan Shokat, Professor, Department of Cellular and Molecular Pharmacology, UCSF, Department of Chemistry, UC Berkeley; Investigator, HHMI
Paul Lammers, CEO, Triumvira Immunologics
Robert Li, Founder & CEO, LTZ Therapeutics
Roy Maute, Co-Founder & CSO, Pheast Therapeutics
Giuseppe Mazza, CEO & Co-Founder, Engitix; Honorary Associate Professor, UCL
Jon Moore, Co-Founder & CEO, Epitopea
Joseph Nabhan, CSO, Vesigen Therapeutics
Taku Nakahara, Founder & CEO, Metagen Therapeutics
Lars Nieba, CEO, Engimmune Therapeutics
Catriona Jamieson, Professor of Medicine and Koman Family Presidential Endowed Chair in Cancer Research, UC San Diego; Founder, Aspera Biomedicines
David Schaffer, Professor, Chemical & Biomolecular Engineering, Bioengineering, and Molecular & Cell Biology, Neuroscience, UC Berkeley
Daisy Robinton, Co-Founder, CEO and Board Director, Oviva Therapeutics
Catherine Sabatos-Peyton, CEO, Larkspur Biosciences
Avencia Sánchez-Mejías, Co-Founder & CEO, Integra Therapeutics
Ishita Shah, CEO & Co-Founder, Matrubials
Nicholas Siciliano, CEO & Co-Founder, Vittoria Biotherapeutics
Uttam Surana, Adjunct Professor, Department of Pharmacology, National University of Singapore; Co-Founder, Aldropika Therapeutics
Leslie Williams, Co-Founder, President & CEO, hC Bioscience
Richard Soll, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec
